SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event reported):
February 6, 2023 (
|(Exact name of registrant as specified in its charter)|
|(State or other jurisdiction
|(IRS Employer Identification No.)|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading
|Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Molekule Group, Inc. (the “Company”) has agreed with Mr. Jonathan Harris, its chief commercial officer, that Mr. Harris’s last day of employment with the Company was effective as of January 31, 2023. In connection with his departure from the Company, Mr. Harris has entered into a separation agreement with the Company which provides that (1) Mr. Harris will receive a lump sum payment of six months of base salary ($175,000), (2) Mr. Harris will retain his 106,710 vested RSUs, which will settle in accordance with their terms within 30 days following July 12, 2023, and will forfeit his unvested RSUs and (3) Mr. Harris will receive medical and dental benefits for a specified period of time.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 6, 2023
|MOLEKULE GROUP, INC.|
|By:||/s/ Jason DiBona|
|Name: Jason DiBona|
|Title: Chief Executive Officer|